This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kindmark, H. Articles by Efendic, S. Search for Related Content PubMed PubMed Citation Articles by Kindmark, H. Articles by Efendic, S.

Glucose-Dependent Insulinotropic Hormone Potentiates the Hypoglycemic Effect of Glibenclamide in Healthy Volunteers: Evidence for an Effect on Insulin Extraction¹

Department of Endocrinology and Diabetology, Karolinska Institutet, Karolinska Hospital, S-171 76 Stockholm, Sweden

Address all correspondence and requests for reprints to: Henrik Kindmark, M.D., Ph.D., Department of Endocrinology and Diabetology D2:02, Karolinska Institute, Karolinska Hospital, S-171 76 Stockholm, Sweden. E-mail: henrik.kindmark{at}ks.sc

Glucose-dependent insulinotropic hormone (GIP) is an intestinal hormone considered to be an important mediator of the incretin effect, i.e. the augmented insulin release observed in response to orally, compared with iv, administered glucose, despite isoglycemic glucose profiles. Stimulation of ß-cell secretion of insulin by GIP is seen both in vitro and in vivo at permissive extracellular glucose concentrations (>6 mmol/L). It has also been claimed that part of the incretin effect is due to decreased insulin extraction. We now show that an infusion of GIP in healthy volunteers in whom blood glucose levels were maintained at 5 mmol/L, increased glibenclamide-stimulated levels of plasma insulin without significantly changing the C peptide profile. The increased plasma insulin levels necessitated extra glucose infusion to maintain euglycemia, demonstrating the biological significance of the elevated insulin levels. Infusion of GIP alone caused neither glucose changes nor elevation of C peptide or insulin levels. Hence, our results show that at a blood glucose concentration of 5 mmol/L, GIP augments the increase in plasma insulin levels stimulated by glibenclamide, possibly acting through a mechanism involving decreased insulin extraction in the liver or peripheral tissues, thus increasing insulin availability.

This article has been cited by other articles:

				D. S. Edgerton, K. M.S. Johnson, D. W. Neal, M. Scott, C. H. Hobbs, X. Zhang, A. Duttaroy, and A. D. Cherrington Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog Diabetes, January 1, 2009; 58(1): 243 - 249. [Abstract] [Full Text] [PDF]

				J. J. Meier, J. J. Holst, W. E. Schmidt, and M. A. Nauck Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E849 - E856. [Abstract] [Full Text] [PDF]

				B. D Green, N. Irwin, V. A Gault, F. P. O'Harte, and P. R Flatt Review: Development and therapeutic potential of incretin hormone analogues for type 2 diabetes The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 134 - 140. [Abstract] [PDF]